Valiant Organics Limited · NSE:VALIANTORG
Valiant Organics — Q1 FY2025 Earnings Presentation
22 slides from Valiant Organics's earnings presentation, Aug 28, 2024
Slide 1: Cover letter to stock exchanges: Results Presentation
August 28, 2024 To, To, Listing/Compliance Department Listing/Compliance Department BSE LTD National Stock Exchange of Phiroze Jeejeebhoy Towers, India Limited Dalal Street, “Exchange Plaza”, Plot No. C/1, Mumbai- 400 001. G Block Bandra-Kurla Complex, Bandra (E), Mumbai- 400 051. SCRIP CODE - 54014
Slide 2: Earnings Presentation | Q1-FY25
Earnings Presentation | Q1 -FY25
Slide 3: Snapshot
SNAPSHOT One of the largest chlorophenol One of the leading manufacturer of derivatives manufacturer globally Benzene derivatives products One of the largest domestic PNA One of the few commercial players in manufacturer Ortho Anisidine and Para Anisidine Diversified client base across Amongst 1st f
Slide 4: Company Overview
Company Overview Valiant Organics Limited was incorporated in 1984 by first generation technocrats and is headquartered out of Mumbai, India. The company is focused on the manufacturing and marketing of specialty chemicals which find usage in a variety of industries, including agrochemicals, pharmac
Slide 5: Chemistries And Product Basket
Chemistries And Product Basket Q1-FY25 Revenue Share Hydrogenation Ammonolysis 40% Key Products: Industries Served: Key Products: • Ortho Anisidine Industries Served: • Dyes • Para Nitro Aniline • Para Anisidine • Dyes • Pigments • Ortho Chloro Para Nitro Aniline • IPPCA • Pigments • Pharmaceutical
Slide 6: Manufacturing Footprint
Manufacturing Footprint CHLORINATION – SARIGAM HYDROGENATION & METHOXYLATION- • Capacity: 18,000 MTPA JHAGADIA UNIT 1 • Products: PCP, OCP, 2,4 DCP, 2,6 DCP, • Capacity: 27,000 MTPA 2,4,6 TCP • Products: ONA/OA, PNA/PA, IPPCA, CONVERSION PRODUCTS AMMONOLYSIS - VAPI HYDROGENATION – JHAGADIA UNIT 2 •
Slide 7: Key Strengths
Key Strengths Domain expertise and broad Plant locations are process understanding in a Wide supply chain strategically located near variety of chemistries. The provides the continuous ports to provide a executive team is made up of availability of adequate competitive advantage, first-generation te
Slide 8: Q1-FY25 Highlights
Q1-FY25 HIGHLIGHTS Valiant Organics Limited | Q1-2025 7
Slide 9: Q1-FY25 Consolidated Financial Highlights
Q1-FY25 CONSOLIDATED FINANCIAL HIGHLIGHTS INR 1,679 Mn Operational Revenue INR 157 Mn Operating EBITDA 9.35% Operating EBITDA Margin INR (6) Mn Profit After Tax (0.36)% PAT Margin INR (0.22)/ Share EPS Valiant Organics Limited | Q1-2025 8
Slide 10: Q1-FY25 Operational Highlights
Q1-FY25 Operational Highlights Q1-FY25 Revenue Break-up – Chemistries • EBITDA improved from negative INR 18 Million in Q4-FY24 to INR 157 Million in Q1-FY25, indicating a Others, 7% significant improvement in operational efficiency which is reflected in the EBITDA margin, which has improved from (1
Slide 11: Key Chemistries: Revenues and Sales Volumes
Key Chemistries Chlorination (INR Mn) Hydrogenation (INR Mn) Ammonolysis (INR Mn) Others (INR Mn) 700 697 700 140 127 549 582 118 543 600 690 REVENUES 600 120 500 475 379 500 100 680 400 327 668 400 80 73 670 300 660 300 60 660 200 200 40 650 100 100 20 0 0 0 640 Q1-FY24 Q4-FY24 Q1-FY25 Q1-FY24 Q4-F
Slide 12: Quarterly Consolidated Financial Performance
Quarterly Consolidated Financial Performance Particulars (INR Mn) Q1-FY25 Q1-FY24 Y-o-Y Q4-FY24 Q-o-Q Revenue from Operations 1,679 2,018 (16.8)% 1,768 (5.0)% Total Expenses 1,522 1,779 (14.4)% 1,786 (14.8)% EBITDA 157 239 (34.3)% (18) NA EBITDA Margins (%) 9.35% 11.84% (249) Bps (1.02)% NA Other In
Slide 13: Quarterly Standalone Financial Performance
Quarterly Standalone Financial Performance Particulars (INR Mn) Q1-FY25 Q1-FY24 Y-o-Y Q4-FY24 Q-o-Q Revenue from Operations 1,679 1,766 (4.9)% 1,768 (5.0)% Total Expenses 1,522 1,563 (2.6)% 1,786 (14.8)% EBITDA 157 203 (22.7)% (18) NA EBITDA Margins (%) 9.35% 11.49% (214) Bps (1.02)% NA Other Income
Slide 14: Historical Financial Overview
HISTORICAL FINANCIAL OVERVIEW Valiant Organics Limited | Q1-2025 13
Slide 15: Historical Consolidated Income Statement
Historical Consolidated Income Statement Particulars (INR Mn) FY22 FY23 FY24 Q1-FY25 Revenue from Operations 11,533 10,518 7,231 1,679 Total Expenses 9,484 8,875 6,849 1,522 EBITDA 2,049 1,643 382 157 EBITDA Margins (%) 17.77% 15.62% 5.28% 9.35% Other Income 74 80 93 4 Depreciation 296 292 349 88 Fi
Slide 16: Consolidated Balance Sheet
Consolidated Balance Sheet Particulars (INR Mn) FY22 FY23 FY24 Particulars (INR Mn) FY22 FY23 FY24 EQUITY 6,489 7,401 7,293 Non-Current Assets 6,652 7,682 8,352 a) Equity Share Capital 272 272 276 a) Property, Plant and Equipment 5,303 6,565 6,297 b) Other Equity 5,856 6,616 7,017 c) Right-Of-Use As
Slide 17: Historical Standalone Income Statement
Historical Standalone Income Statement Particulars (INR Mn) FY22 FY23 FY24 Q1-FY25 Revenue from Operations 9,484 9,116 6,772 1,679 Total Expenses 7,811 7,817 6,376 1,522 EBITDA 1,673 1,299 396 157 EBITDA Margins (%) 17.64% 14.25% 5.85% 9.35% Other Income 33 29 29 4 Depreciation 273 276 340 88 Financ
Slide 18: Standalone Balance Sheet
Standalone Balance Sheet Particulars (INR Mn) FY22 FY23 FY24 Particulars (INR Mn) FY22 FY23 FY24 EQUITY 6,031 6,661 6,649 Non-Current Assets 6,787 7,424 7,818 a) Equity Share Capital 272 272 276 a) Property, Plant and Equipment 5,085 6,092 6,297 b) Other Equity 5,755 6,385 6,373 b) Right-Of-Use Asse
Slide 19: Consolidated Financial Highlights
Consolidated Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 11,533 1,400 1,279 10,518 2,049 10,000 1,643 1,100 1,026 7,500 7,231 800 5,000 500 17.77% 15.62% 382 1,679 157 11.09% 9.75% 2,500 200 5.28% 9.35% -84 -6 - -100 FY22 FY23
Slide 20: Capital Market Information
Capital Market Information Share Price up to 30th June, 2024 30% 10% -10% -30% -50% -70% Jul-23 Aug-23 Sep-23 Oct-23 Nov-23 Dec-23 Jan-24 Feb-24 Mar-24 Apr-24 May-24 Jun-24 Valiant Organics Sensex Shareholding pattern (As on 30th June, 2024) Price Data (As on 30th June, 2024) INR FII; 1.35% DII; 0.0
Slide 21: Disclaimer
Disclaimer Valiant Organics Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all event
Slide 22: Thank You
THANK YOU Valiant Organics Limited | Q1-2025 21